Skip to main content

Home/ Dr. Goodyear/ Group items tagged triple negative breast cancer

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expec... - 0 views

www.nature.com/ja201711

Ivermectin cancer

shared by Nathan Goodyear on 19 Mar 18 - No Cached
  • The avermectins are known to possess pronounced antitumor activity
  • Over the past few years, there have been steadily increasing reports that ivermectin may have varying uses as an anti-cancer agent, as it has been shown to exhibit both anti-cancer and anti-cancer stem cell properties
  • In human ovarian cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1-dependent growth
  • ...13 more annotations...
  • PAK1 is essential for the growth of more than 70% of all human cancers, including breast, prostate, pancreatic, colon, gastric, lung, cervical and thyroid cancers, as well as hepatoma, glioma, melanoma, multiple myeloma and for neurofibromatosis tumors
  • Ivermectin suppresses breast cancer by activating cytostatic autophagy, disrupting cellular signaling in the process, probably by reducing PAK1 expression
  • Cancer stem cells are a key factor in cancer cells developing resistance to chemotherapies and these results indicate that a combination of chemotherapy agents plus ivermectin could potentially target and kill cancer stem cells, a paramount goal in overcoming cancer
  • Triple-negative breast cancers, which lack estrogen, progesterone and HER2 receptors, account for 10–20% of breast cancers and are associated with poor prognosis
  • Ivermectin addition led to transcriptional modulation of genes associated with epithelial–mesenchymal transition and maintenance of a cancer stem cell phenotype in triple-negative breast cancers cells, resulting in impairment of clonogenic self-renewal in vitro and inhibition of tumor growth and metastasis in vivo
  • ivermectin synergizes with the chemotherapy agents cytarabine and daunorubicin to induce cell death in leukemia cells
  • Ivermectin-induced cytostatic autophagy also leads to suppression of tumor growth in breast cancer xenografts, causing researchers to believe there is scope for using ivermectin to inhibit breast cancer cell proliferation and that the drug is a potential treatment for breast cancer
  • Ivermectin inhibits proliferation and increases apoptosis of various human cancers
  • Activation of WNT-TCF signaling is implicated in multiple diseases, including cancers of the lungs and intestine,
  • A new screening system has found that ivermectin inhibits the expression of WNT-TCF targets
  • It represses the levels of C-terminal β-catenin phosphoforms and of cyclin D1 in an okadaic acid-sensitive manner, indicating its action involves protein phosphatases
  • In vivo, ivermectin selectively inhibits TCF-dependent, but not TCF-independent, xenograft growth without side effects
  • ivermectin has an exemplary safety record, it could swiftly become a useful tool as a WNT-TCF pathway response blocker to treat WNT-TCF-dependent diseases, encompassing multiple cancers.117
  • Nathan Goodyear on 19 Mar 18
     
    Ivermectin shows promise and usefullness in several cancer types.  This is a review article.
Nathan Goodyear

Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin indu... - 0 views

www.ncbi.nlm.nih.gov/...PMC4639773

ivermectin cancer breast cancer

shared by Nathan Goodyear on 20 Mar 18 - No Cached
  • ATP can function as a prototypical danger signal that activates a potent immune response, but can also promote cancer progression
  • tumor growth and survival appears to critically
  • our findings indicate that Ivermectin may kill cancer cells though a mechanism combining apoptosis and necrosis/pyroptosis
  • ...1 more annotation...
  • Ivermectin has recently been shown to have anti-tumor properties that we hereby link to its ability to augment P2X4/P2X7/Pannexin-1 signaling and caspase-1 activation, which is also associated with cancer cells’ elevated expression of P2X4/P2X7 receptors
  • Nathan Goodyear on 20 Mar 18
     
    Ivermectin shown to induce apoptosis, necrosis, and autophagy in shows syngergist activity with chemotherapy.  This was shown in triple negative breast cancer cell lines which are more resistent to therapy.
Nathan Goodyear

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cel... - 0 views

breast-cancer-research.biomedcentral.com/...s13058-019-1204-2

cisplatin breast cancer metformin triple negative breast cancer

shared by Nathan Goodyear on 05 Aug 21 - No Cached
  • Nathan Goodyear on 05 Aug 21
     
    Metformin restores chemosensitivity in TNBC.
Nathan Goodyear

Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5718030

chloroquine hydroxychloroquine cancer repurposed drugs

shared by Nathan Goodyear on 03 May 21 - No Cached
  • HCQ, doses for long-term use range between 200 and 400 mg per day.
  • Short-term administration of CQ or HCQ rarely causes severe side effects
  • Short-term administration of CQ or HCQ rarely causes severe side effects
  • ...24 more annotations...
  • bone marrow suppression
  • cardiomyopathy
  • irreversible retinal toxicity
  • hypoglycaemia
  • daily doses up to 400 mg of HCQ or 250 mg CQ for several years are considered to carry an acceptable risk for CQ-induced retinopathies, with the exception of individuals of short stature
  • chronic CQ or HCQ therapy be monitored through regular ophthalmic examinations (3–6 month intervals), full blood counts and blood glucose level checks
  • long-term HCQ exposure, skeletal muscle function and tendon reflexes should be monitored for weakness
  • both CQ and HCQ, specific caution is advised in patients suffering from impaired hepatic function (especially when associated with cirrhosis), porphyria, renal disease, epilepsy, psoriasis, glucose-6-phosphate dehydrogenase deficiency and known hypersensitivity to 4-aminoquinoline compounds
  • CQ and HCQ can effectively increase the efficacy of various anti-cancer drugs
  • CQ can prevent the entrapment of protonated chemotherapeutic drugs by buffering the extracellular tumour environment and intracellular acidic spaces
  • This study recommends an adjuvant HCQ dose of 600 mg, twice daily.
  • HCQ addition was shown to produce metabolic stress in the tumours
  • HCQ (400 mg/day)
  • important effects of CQ and HCQ on the tumour microenvironment
  • The main and most studied anti-cancer effect of CQ and HCQ is the inhibition of autophagy
  • the expression levels of TLR9 are higher in hepatocellular carcinoma, oesophageal, lung, breast, gastric and prostate cancer cells as compared with adjacent noncancerous cells, and high expression is often linked with poor prognosis
  • TLR9-mediated activation of the NF-κB signalling pathway and the associated enhanced expression of matrix metalloproteinase-2 (MMP-2), MMP-7 and cyclo-oxygenase 2 mRNA
  • HCQ can activate caspase-3 and modulate the Bcl-2/Bax ratio inducing apoptosis in CLL, B-cell CLL and glioblastoma cells
  • In triple-negative breast cancer, CQ was shown to eliminate cancer stem cells through reduction of the expression of Janus-activated kinase 2 and DNA methyl transferase 1 [106] or through induction of mitochondrial dysfunction, subsequently causing oxidative DNA damage and impaired repair of double-stranded DNA breaks
  • CQ or HCQ would be considered for use in combination with immunomodulation anti-cancer therapies
  • Therapies used in combination with CQ or HCQ include chemotherapeutic drugs, tyrosine kinase inhibitors, various monoclonal antibodies, hormone therapies and radiotherapy
  • Most studies hypothesise that CQ and HCQ could increase the efficacy of other anti-cancer drugs by blocking pro-survival autophagy.
  • daily doses between 400 and 1200 mg for HCQ are safe and well tolerated, but two studies identified 600-mg HCQ daily as the MTD
  • HCQ is often administered twice daily to limit plasma fluctuations and toxicity
Nathan Goodyear

The use of chemosensitizers to enhance the response to conventional therapy in triple-n... - 0 views

www.futuremedicine.com/...bmt-2017-0030

breast cancer curcumin triple negative breast cancer cancer

shared by Nathan Goodyear on 10 May 19 - No Cached
  • Nathan Goodyear on 10 May 19
     
    Curcumin increases sensitivity of chemotherapy and reduces side effects of chemotherapy.
Nathan Goodyear

The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-nega... - 0 views

www.ncbi.nlm.nih.gov/...30660598

breast cancer cancer artesunate

shared by Nathan Goodyear on 01 Jul 19 - No Cached
  • Nathan Goodyear on 01 Jul 19
     
    ART inhibited breast cancer cell proliferation via a reactive oxygen species (ROS)-dependent G2/M arrest and ROS-independent G1 arrest. ART-treated MDA-MB-468 and SK-BR-3 cells also experienced apoptotic cell death, which was both ROS- and iron-dependent. ART-induced oxidative stress caused the loss of mitochondrial outer membrane integrity and damage to the cellular DNA of MDA-MB-468 and SK-BR-3 cells. Only abstract available...I will post full article once available.
Nathan Goodyear

Combined treatment with vitamin C and methotrexate inhibits triple-negative breast canc... - 0 views

www.spandidos-publications.com/...or.2017.5439

IV vitamin C breast cancer EGFR triple negative breast cancer vitamin C TNBC Caspase-3 methotrexate

shared by Nathan Goodyear on 15 Mar 21 - No Cached
  • Nathan Goodyear on 15 Mar 21
     
    Low dose methotrexate + low dose vitamin C inhibit TNBC via EGFR mechanism
Nathan Goodyear

The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Mo... - 0 views

journals.plos.org/...article

Neutrophil:lymphocyte "breast cancer" "triple negative breast cancer

shared by Nathan Goodyear on 24 Dec 18 - No Cached
  • Nathan Goodyear on 24 Dec 18
     
    Neutrophil:Lymphocyte ratio more valuable than LMR in TNBC
Nathan Goodyear

Synergistic anticancer action of quercetin and curcumin against triple-negative breast ... - 0 views

triple negative breast cancer quercetin breast cancer curcumin

shared by Nathan Goodyear on 10 May 19 - No Cached
  • Nathan Goodyear on 10 May 19
     
    Must read of the synergistic effects of quercetin and curcumin in TNBC.
Nathan Goodyear

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic... - 0 views

journals.plos.org/...article

"Breast cancer" androgen receptor AR HER-2

shared by Nathan Goodyear on 19 Nov 18 - No Cached
  • Nathan Goodyear on 19 Nov 18
     
    Androgen receptor status helps to determine prognosis in breast cancer. High risk is AR-/HER-2+ and low risk is AR+/HER-2-
Nathan Goodyear

Amygdalin Regulates Apoptosis and Adhesion in Hs578T Triple-Negative Breast Cancer Cells - 1 views

www.ncbi.nlm.nih.gov/...PMC4703354

amygdalin breast cancer B17

shared by Nathan Goodyear on 17 Jul 19 - No Cached
  • Nathan Goodyear on 17 Jul 19
     
    Cell study finds that amygdalin inhibits cell proliferation and induces cytotoxicity in multiple breast cancer cell lines, including TNBC.
Nathan Goodyear

Cureus | Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet,... - 1 views

www.cureus.com/...-triple-negative-breast-cancer

ketogenic diet hbot hyperbaric oxygen hyperbaric therapy diet nutrition cancer hyperthermic therapy chemotherapy

shared by Nathan Goodyear on 09 Jul 17 - No Cached
  • Nathan Goodyear on 09 Jul 17
     
    Asking questions that challenge dogma is difficult.  This individual case study just does that.  Case study finds that ketogenic diet, hyperthermic therapy, and hyperbaric oxygen reduce the side effects of chemo, improved quality of life, and at the time of the publication, remission of disease.
1 - 20 of 30 Next ›
Showing 20▼ items per page